Search Existing Participant Requests

The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.


Search Terms:


Investigator: Andrei Vlassenko

Project Title: Aerobic Glycolysis in the Development of Alzheimer�s Disease

Date: September 8, 2017

Request ID: S1706

Aim 1: Evaluate the role of AG as a function of preclinical and symptomatic stages of AD, and determine whether baseline AG predicts the rate of change in other biomarkers and cognitive measures, and if low baseline AG will be associated with the subsequent development of AD pathology and cognitive decline

Aim 2: Determine rate of change in AG in relation to rate of change in clinical assessments and biomarkers of AD; evaluate changes in AG and other PET measures of metabolism and circulation during the transition from no AD pathology to preclinical AD, and through the preclinical stages to symptomatic AD.

Aim 3:

Aim 4:


Investigator: Dmitriy Yablonskiy

Project Title: In vivo MRI Biomarkers of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease

Date: July 21, 2017

Request ID: S1705

Aim 1: To develop a readily available, non-invasive quantitative in vivo MRI-based biomarker that can serve as a surrogate for Aβ accumulation in the brain

Aim 2: To establish specific quantitative and spatial patterns of GEPCI metrics abnormalities that would distinguish between normal brain, preclinical AD, and very mild AD

Aim 3: To test the hypothesis that the GEPCI metrics and/or changes in GEPCI metrics can be predictors of the disease progression

Aim 4: To validate GEPCI measurements against direct neuropathology


Investigator: Yi Su

Project Title: Absolute Quantification of Amyloid PET

Date: April 20, 2017

Request ID: S1704

Aim 1: Validating a reference region free method for amyloid PET quantification

Aim 2:

Aim 3:

Aim 4:


Investigator: Todd Braver

Project Title: Interaction of Motivation and Cognitive Control in Older Adult Decision Making

Date: April 14, 2017

Request ID: S1703

Aim 1: Examine age differences in cognitive control mechanisms that enable motivational integration

Aim 2:

Aim 3:

Aim 4:


Investigator: Jeffrey M. Zacks

Project Title: Everyday Memory in Aging and Alzheimer’s Disease

Date: March 27, 2017

Request ID: S1702

Aim 1: Test the hypothesis that age and biomarkers for AD neuropathology are associated with impairments in the ability to notice and remember changes.

Aim 2: Use an experimental approach to test one potential mechanism: reduced fidelity of medial temporal activity patterns leading to impaired detection of discrepancy.

Aim 3: Attempt to remediate age- and AD-related memory deficits by enhancing elders� encoding of new events in relation to related previous events with a cuing procedure.

Aim 4:


Investigator: John C. Morris

Project Title: Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer�s Disease

Date: March 14, 2017

Request ID: S1701

Aim 1: To show that loss of blood-brain barrier (BBB) integrity links vascular injury to neuronal injury in AD

Aim 2: Examine temporal relationship between BBB permeability, cerebral blood flow (CBF) and white matter lesions

Aim 3:

Aim 4:


Investigator: Jason Hassenstab

Project Title: Pilot Study: Ambulatory Cognitive Assessments

Date: October 26, 2016

Request ID: S1610

Aim 1: Determine the feasibility and utility of ambulatory cognitive assessments using measurment burst design.

Aim 2:

Aim 3:

Aim 4:


Investigator: Ganesh Babulal

Project Title: Racial differences in Alzheimer�s disease biomarkers and driving behavior

Date: October 18, 2016

Request ID: S1609

Aim 1: We will determine, in a sample of 60 older adults, aged 65 years and older, with normal baseline cognition (Clinical Dementia Rating of 0), whether there are differences in values of cerebrospinal fluid (CSF) biomarkers and imaging amyloid uptake between African Americans and Caucasians

Aim 2: In the same sample, we will examine whether there are differences in African Americans and Caucasians cross-sectionally and longitudinally in daily driving behavior using an in-vehicle recording device and on a road test

Aim 3:

Aim 4:


Investigator: Eric McDade

Project Title: Cerebrovascular Reactivity in the Presence of Cerebral Amyloid and Cerebrovascular Disease:

Date: August 21, 2016

Request ID: S1608

Aim 1: To explore the impact of cerebral amyloid on cerebrovascular reactivity

Aim 2: To explore the impact of age and vascular related comorbidities in the relationship of cerebrovascular reactivity and cerebral amyloid

Aim 3: To explore the the impact of cerebrovascular reactivity as a moderator of amyloid related cognitive impairment

Aim 4:


Investigator: B, Joy Snider (WU site)

Project Title: Protocol 221AD301 A phase 3 Multicenter, RCT to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer�s Disease (ENGAGE Study)

Date: August 17, 2016

Request ID: S1607

Aim 1: Evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo in subjects with early AD.

Aim 2: Evaluate the efficacy of aducanumab on MMSE, ADAS-Cog13, ADCS-ADL

Aim 3:

Aim 4: